The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F- Fluoride PET/CT

Journal of Nuclear Medicine

Volumn 47, Issue 2, 2006, Pages 287-297

  Even Sapir, Einat ^a,b   Metser, Ur ^a,b   Mishani, Eyal ^c   Lievshitz, Gennady ^a   Lerman, Hedva ^a   Leibovitch, Ilan ^b,d  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d MEIR MEDICAL CENTER   (Israel)

Author keywords

18F Fluoride; Bone metastases; PET CT; Prostate cancer; SPECT

Indexed keywords

FLUORINE 18; MEDRONATE TECHNETIUM TC 99M; DIAGNOSTIC AGENT; FLUORINE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER DIAGNOSIS; CANCER RISK; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DRUG UPTAKE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MALE; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; BONE TUMOR; COMPARATIVE STUDY; IMAGE SUBTRACTION; METASTASIS; METHODOLOGY; PROSTATE TUMOR; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; THREE DIMENSIONAL IMAGING;

AGED; BONE NEOPLASMS; FLUORINE RADIOISOTOPES; HUMANS; IMAGING, THREE-DIMENSIONAL; MALE; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SUBTRACTION TECHNIQUE; TECHNETIUM TC 99M MEDRONATE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33746187320     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Hricak H, Schoder H, Pucar D, et al. Advances in imaging in the postoperative patient with a rising prostate-specific antigen level. Semin Oncol. 2003;30: 616-634.
2. Han M, Partin AW, Zahurak M, et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003;169:517-523.
3. Schoder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med. 2004;34:274-292.
4. Abuzallouf S, Dayes I, Lukka H. Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol. 2004;171:2122-2127.
5. Lee N, Fawaaz R, Olsson CA, et al. Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients. Int J Rad Oncol Biol Phys. 2000;48:1443-1446.
6. Fogelman I, Cook G, Israel O, et al. Positron emission tomography and bone metastases. Semin Nucl Med. 2005;35:135-142.
7. Wymenga LFA, Boomsma JHB, Groenier K, et al. Routine bone scans in patients with prostate related to serum prostate-specific antigen and alkaline phosphatase. BJU Int. 2001;88:226-230.
8. Yap VK, Choo R, Klotz L, et al. Are serial bone scans useful for the follow-up of clinically localized, low to intermediate grade prostate cancer managed with watchful observation alone? BJU Int. 2003;91:613-617.
9. Gomez P, Manoharan M, Kim SS, et al. Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated? BJU Int. 2004;94:299-302.
10. Sabbatini P, Larson SM, Kremer A. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol. 1999;17:948-957.
11. Rigaud J, Tiguert R, Le Normand L. Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy. J Urol. 2002;168:1423-1426.
12. 18F PET. J Nucl Med. 1999;40:1623-1629.
13. 18F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med. 2001;42:1800-1804.
14. Jacobson AF, Fogelman I. Bone scanning in clinical oncology: does it have a future? Eur J Nucl Med. 1998;25:1219-1223.
15. Gates GF. SPECT bone scanning of the spine. Semin Nucl Med. 1998;28:78-94.
16. Cook GJ, Fogelman I. The role of positron emission tomography in skeletal disease. Semin Nucl Med. 2001;31:50-61.
17. Schirrmeister H, Guhlnamm A, Kotzerke J, et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol. 1999;17:2381-2389.
18. Ghanem N, Uhl M, Brink I, et al. Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone. Eur J Radiol. 2005;55:41-55.
19. Shreve PD, Grossman HB, Gross MD, et al. Metastatic prostate cancer: initial finding of PT 2-deoxyglucose-[F-18]fluoro-D-glucose. Radiology. 1996;199: 751-756.
20. Morris MJ, Akhurst T, Osman I, et al. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology. 2002;59:913-918.
21. 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2003;30:607-611.
22. 18F]Fluoro-2- deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res. 2005;11: 4761-4769.
23. Oyen WJG, Witjes JA, Corstens FHM. Nuclear medicine techniques for the diagnosis and therapy of prostate carcinoma. Eur Urol. 2001;40:294-299.
24. Hawkins RA, Choi Y, Huang SC, et al. Evaluation of skeletal kinetics of fluorine 18-fluoride ion and PET. J Nucl Med. 1992;33:633-642.
25. Schiepers C, Nuytes J, Bormans G, et al. Fluoride kinetics of the axial skeleton measured in vivo with fluorine-18-fluoride PET. J Nucl Med. 1997;38:1970-1976.
26. Hoegerle S, Juengling F, Otte A, et al. Combined FDG and F-18-fluoride whole body PET: a feasible two-in-one approach to cancer imaging. Radiology. 1998;209: 253-258.
27. 18F-fluoride PET/CT. J Nucl Med. 2004;45:272-278.
28. Song X, Segars WP, Du Y, et al. Fast modeling of the collimator-detector response in Monte Carlo simulation of SPECT imaging using the angular response function. Phys Med Biol. 2005;21:1791-1804.
29. Even-Sapir E, Martin RH, Barnes DC, et al. Role of SPECT in differentiating malignant from benign lesions in the lower thoracic and lumbar vertebrae. Radiology. 1993;187:193-198.
30. Thurairaja R, McFarlane J, Traill Z, et al. State-of-the-art approaches to detecting early bone metastasis in prostate cancer. BJU Int. 2004;94:268-271.
31. Blake GM, Park-Holoan SJ, Cook GJR, et al. Quantitative studies of bone with the use of F18-fluoride and Tc99m-methylene miphosphonate. Semin Nucl Med. 2001;1:28-49.
32. Uematsu T, Yuen S, Yukisawa S, et al. Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer. AJR. 2005;184:1266-1273.
33. Savelli G, Maffioli L, Maccauro M, et al. Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions. Q J Nucl Med. 2001;45:27-37.